TP53 and breast carcinoma: In breast cancer cells, mutant p53, which is the most frequent target for mutation in tumors, contributes to the upregulation of the mevalonate pathway, through recruitment of many sterol biosynthesis genes, or probably through one or more of the SREBP proteins (88).